The Histone-Lysine N-Methyltransferase (KMT2) Family in Health and Disease

Abstract

The histone-lysine N-methyltransferase (KMT2) family is a central epigenetic regulator whose dysfunction drives diverse human diseases through distinct molecular mechanisms. In acute leukemias, KMT2A rearrangements aberrantly recruit transcriptional cofactors, activating oncogenic gene programs; in solid tumors, loss-of-function mutations in KMT2C/D disrupt enhancer-mediated regulatory networks, compromising cellular identity and genome stability; in neurodevelopmental disorders, germline haploinsufficiency of KMT2A/B/D impairs developmental epigenetic programming. Despite increasingly comprehensive understanding of the pathogenic mechanisms involving KMT2 family members, a unified framework translating these molecular insights into effective, subtype-specific therapeutic strategies has been lacking. This review comprehensively deconstructs these pathogenic pathways and explores how mechanistic insights are being translated into novel therapeutic strategies, including direct targeting of oncogenic transcriptional complexes, exploiting vulnerabilities from tumor suppressor loss, and modulating the tumor immune microenvironment. We systematically synthesize recent clinical advances, from small-molecule inhibitors against protein–protein interactions (e.g., menin–KMT2A), to targeted degraders (PROTACs), epigenetic readers/writers inhibitors (e.g., BET, LSD1, DOT1L), and rational combination regimens with chemotherapy or immunotherapy. By integrating the biological characteristics of KMT2 with translational medicine and clinical evidence, this study provides a framework for advancing precision medicine approaches based on the molecular subtypes driven by KMT2.

Keywords

disease / epigenetics / KMT2 family / therapy

References

[1] W. Du, G. Shi, C. M. Shan, et al., “Mechanisms of Chromatin-based Epigenetic Inheritance,” Science China Life sciences 65, no. 11 (2022): 2162–2190.

[2] G. Millán-Zambrano, A. Burton, A. J. Bannister, et al., “Histone Post-translational Modifications—cause and Consequence of Genome Function,” Nature Reviews Genetics 23, no. 9 (2022): 563–580.

[3] W. C. Hsieh, B. M. Sutter, H. Ruess, et al., “Glucose starvation induces a switch in the histone acetylome for activation of gluconeogenic and fat metabolism genes,” Molecular cell 82, no. 1 (2022): 60–74.

[4] A. M. Stroynowska-Czerwinska, M. Klimczak, M. Pastor, et al., “Clustered PHD Domains in KMT2/MLL Proteins Are Attracted by H3K4me3 and H3 Acetylation-rich Active Promoters and Enhancers,” Cellular and Molecular Life Sciences 80, no. 1 (2023): 23.

[5] E. Poreba, K. Lesniewicz, and J. Durzynska, “Histone-lysine N-methyltransferase 2 (KMT2) Complexes—a New Perspective,” Mutation Research/Reviews in Mutation Research 790 (2022): 108443.

[6] H. T. Van, G. Xie, and P. Dong, “KMT2 Family of H3K4 Methyltransferases: Enzymatic Activity-dependent and -independent Functions,” Journal of Molecular Biology 436, no. 7 (2024): 168453.

[7] M. Jamali, E. Barar, and J. Shi, “Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights Into the Role of the COMPASS-Like Complex,” International Journal of Molecular Sciences 25, no. 10 (2024): 5069.

[8] L. Yin, J. Zhang, Z. Zhu, et al., “The FBXW7-KMT2 Axis in Cancer-associated Fibroblasts Controls Tumor Growth via an Epigenetic-paracrine Mechanism,” Pnas U S A 122, no. 13 (2025): e2423130122.

[9] H. M. Amin, B. Szabo, R. Abukhairan, et al., “In Vivo and In Vitro Characterization of the RNA Binding Capacity of SETD1A (KMT2F),” International Journal of Molecular Sciences 24, no. 22 (2023): 16032.

[10] S. Meng, H. Shi, C. Lin, et al., “UvKmt2-Mediated H3K4 Trimethylation Is Required for Pathogenicity and Stress Response in Ustilaginoidea Virens,” J Fungi (Basel) 8, no. 6 (2022): 553.

[11] J. Wang, J. Xiu, Y. Baca, et al., “Large-scale Analysis of KMT2 Mutations Defines a Distinctive Molecular Subset With Treatment Implication in Gastric Cancer,” Oncogene 40, no. 30 (2021): 4894–4905.

[12] G. C. Issa, I. Aldoss, M. J. Thirman, et al., “Menin Inhibition with Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101),” Journal of Clinical Oncology 43, no. 1 (2025): 75–84.

[13] I. Iacobucci and C. G. Mullighan, “KMT2A-rearranged leukemia: the shapeshifter,” Blood 140, no. 17 (2022): 1833–1835.

[14] G. C. Issa, I. Aldoss, J. DiPersio, et al., “The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia,” Nature 615, no. 7954 (2023): 920–924.

[15] E. Hissong, L. Zhao, and J. Shi, “Clinicopathologic and Molecular Features of Pancreatic Ductal Adenocarcinomas Harboring Alterations in COMPASS-Like Complex Genes,” Archives of Pathology & Laboratory Medicine 147, no. 9 (2023): 1050–1059.

[16] M. C. Hsu, Y. F. Chen, and H. Yamaguchi, “KMT2C mutations in Breast Cancer: Molecular Mechanisms of Cancer Promotion, Clinical Significance, and Potential as Biomarkers,” Critical Reviews in Oncology/Hematology 217 (2025): 105004.

[17] M. Boutet, K. Nishitani, N. Couturier, et al., “Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells,” Immunity 58, no. 8 (2025): 2035–2053.e9.

[18] R. C. Rao and Y. Dou, “Hijacked in Cancer: The KMT2 (MLL) family of Methyltransferases,” Nature Reviews Cancer 15, no. 6 (2015): 334–346.

[19] R. Ng, L. Meier, A. O'Donnell-Luria, et al., “Academic Learning Profiles across Disorders of KMT2 Gene Family: Superimposed and Distinct Features across Kabuki, Wiedemann-Steiner and ODLURO Syndromes,” Jidr 69, no. 11 (2025): 1295–1303.

[20] W. J. Lavery, A. Barski, S. Wiley, et al., “KMT2C/D COMPASS Complex-associated Diseases [K(CD)COM-ADs]: An Emerging Class of Congenital Regulopathies,” Clin Epigenetics 12, no. 1 (2020): 10.

[21] H. Jiang, “The Complex Activities of the SET1/MLL Complex Core Subunits in Development and Disease,” Biochim Biophys Acta Gene Regul Mech 1863, no. 7 (Jul 2020): 194560.

[22] Y. Li, L. Zhao, Y. Zhang, et al., “Structural basis for product specificities of MLL family methyltransferases,” Molecular cell 82, no. 20 (2022): 3810–3825.

[23] K. E. W. Namitz, S. A. Showalter, and M. S. Cosgrove, “Phase Separation Promotes a Highly Active Oligomeric Scaffold of the MLL1 Core Complex for Regulation of Histone H3K4 Methylation,” Journal of Biological Chemistry 299, no. 10 (2023): 105204.

[24] S. Rahman, N. A. Hoffmann, E. J. Worden, et al., “Multistate Structures of the MLL1-WRAD Complex Bound to H2B-ubiquitinated Nucleosome,” Pnas U S A 119, no. 38 (2022): e2205691119.

[25] A. F. Bryan, J. Wang, G. C. Howard, et al., “WDR5 is a Conserved Regulator of Protein Synthesis Gene Expression,” Nucleic Acids Research 48, no. 6 (2020): 2924–2941.

[26] Y. T. Lee, A. Ayoub, S. H. Park, et al., “Mechanism for DPY30 and ASH2L Intrinsically Disordered Regions to Modulate the MLL/SET1 Activity on Chromatin,” Nature Communications 12, no. 1 (2021): 2953.

[27] M. Kwon, K. Park, K. Hyun, et al., “H2B ubiquitylation Enhances H3K4 Methylation Activities of human KMT2 family Complexes,” Nucleic Acids Research 48, no. 10 (2020): 5442–5456.

[28] E. Bahena-Culhuac, M. Hernández-Somilleda, and J. M. Hernández-Hernández, “Insights into WDR5: Unveiling its functions, regulation, and impact on skeletal muscle,” Epigenetics 20, no. 1 (2025): 2573998.

[29] L. Liu, X. Guo, Y. Wang, et al., “Loss of Wdr5 Attenuates MLL-rearranged Leukemogenesis by Suppressing Myc Targets,” Biochim Biophys Acta Mol Basis Dis 1869, no. 2 (2023): 166600.

[30] A. D. Guarnaccia and W. P. Tansey, “Moonlighting With WDR5: A Cellular Multitasker,” Journal of Clinical Medicine 7, no. 2 (2018): 21.

[31] M. Ma, J. Zhou, Z. Ma, et al., “The Ash2l SDI Domain Is Required to Maintain the Stability and Binding of DPY30,” Cells 11, no. 9 (2022): 1450.

[32] L. Zhao, N. Huang, J. Mencius, et al., “DPY30 acts as an ASH2L-specific stabilizer to stimulate the enzyme activity of MLL family methyltransferases on different substrates,” Iscience 25, no. 9 (2022): 104948.

[33] M. Barsoum, R. Sayadi-Boroujeni, A. T. Stenzel, et al., “Sequential deregulation of histone marks, chromatin accessibility and gene expression in response to PROTAC-induced degradation of ASH2L,” Scientific Reports 13, no. 1 (2023): 22565.

[34] A. Bochyńska, A. T. Stenzel, and R. Sayadi Boroujeni, “Induction of Senescence Upon Loss of the Ash2l Core Subunit of H3K4 Methyltransferase Complexes,” Nucleic acids research 50, no. 14 (2022): 7889–7905.

[35] K. E. W. Namitz, S. Tan, and M. S. Cosgrove, “Hierarchical Assembly of the MLL1 Core Complex Regulates H3K4 Methylation and Is Dependent on Temperature and Component Concentration,” Journal of Biological Chemistry 299, no. 2 (2023): 102874.

[36] H. Wang, Z. Fan, P. V. Shliaha, et al., “H3K4me3 regulates RNA Polymerase II Promoter-proximal Pause-release,” Nature 615, no. 7951 (2023): 339–348.

[37] G. C. Issa, F. Ravandi, C. D. DiNardo, et al., “Therapeutic Implications of Menin Inhibition in Acute Leukemias,” Leukemia 35, no. 9 (2021): 2482–2495.

[38] F. Perner, J. Y. Gadrey, S. A. Armstrong, et al., “Targeting the Menin-KMT2A Interaction in Leukemia: Lessons Learned and Future Directions,” International Journal of Cancer 158, no. 2 (2026): 342–356.

[39] S. Zehtabcheh, H. Soleimani Samarkhazan, and M. Asadi, “Insights Into KMT2A Rearrangements in Acute Myeloid Leukemia: From Molecular Characteristics to Targeted Therapies,” Biomarker Research 13, no. 1 (2025): 73.

[40] E. Koutná, V. Lux, T. Kouba, et al., “Multivalency of Nucleosome Recognition by LEDGF,” Nucleic Acids Research 51, no. 18 (2023): 10011–10025.

[41] L.-H. Wang, M. A. E. Aberin, S. Wu, et al., “The MLL3/4 H3K4 Methyltransferase Complex in Establishing an Active Enhancer Landscape,” Biochemical Society Transactions 49, no. 3 (2021): 1041–1054.

[42] K. C. LaRue-Nolan, G. L. Raja Arul, and A. N. Sigafoos, “Insights Into the Mechanisms Driven by H3K4 KMTs in Pancreatic Cancer,” Biochemical Journal 481, no. 15 (2024): 983–997.

[43] J. Wei, M. M. Alfajaro, W. L. Cai, et al., “The KDM6A-KMT2D-p300 Axis Regulates Susceptibility to Diverse Coronaviruses by Mediating Viral Receptor Expression,” Plos Pathogens 19, no. 7 (2023): e1011351.

[44] G. Xie, J. E. Lee, A. D. Senft, et al., “MLL3/MLL4 methyltransferase Activities Control Early Embryonic Development and Embryonic Stem Cell Differentiation in a Lineage-selective Manner,” Nature Genetics 55, no. 4 (2023): 693–705.

[45] A. L. Hughes, J. R. Kelley, and R. J. Klose, “Understanding the Interplay Between CpG Island-associated Gene Promoters and H3K4 Methylation,” Biochim Biophys Acta Gene Regul Mech 1863, no. 8 (2020): 194567.

[46] B. Lüscher, P. Bussmann, and J. Müller, “Role of Histone H3 Lysine 4 Methylation in Chromatin Biology,” Molecules (Basel, Switzerland) 30, no. 20 (2025): 4075.

[47] T. Fan, C. Xiao, H. Liu, et al., “CXXC finger protein 1 (CFP1) bridges the reshaping of genomic H3K4me3 signature to the advancement of lung adenocarcinoma,” Signal Transduction and Targeted Therapy 8, no. 1 (2023): 369.

[48] S. Wang, A. Bleeck, and N. Nadif Kasri, “SETD1A Mediated H3K4 Methylation and Its Role in Neurodevelopmental and Neuropsychiatric Disorders,” Front Mol Neurosci 14 (2021): 772000.

[49] Z. Lin, B. Rong, M. Wu, et al., “The KMT2 complex protein ASH2L is required for meiotic prophase progression but dispensable for mitosis in differentiated spermatogonia,” Development (Cambridge, England) 152, no. 6 (2025): dev204630.

[50] M. Barsoum, A. T. Stenzel, A. Bochyńska, et al., “Loss of the Ash2l subunit of histone H3K4 methyltransferase complexes reduces chromatin accessibility at promoters,” Scientific Reports 12, no. 1 (2022): 21506.

[51] J. Sugeedha, J. Gautam, and S. Tyagi, “SET1/MLL family of Proteins: Functions Beyond Histone Methylation,” Epigenetics 16, no. 5 (2021): 469–487.

[52] C. Davidovich and Q. Zhang, “Allosteric Regulation of Histone Lysine Methyltransferases: From Context-specific Regulation to Selective Drugs,” Biochemical Society Transactions 49, no. 2 (2021): 591–607.

[53] V. Kumar Sinha, Y. Zhang, and L. Xu, “Histone H4K16ac Binding Function of the Triple PHD Finger Cassette of MLL4,” Journal of Molecular Biology 436, no. 7 (2024): 168212.

[54] J. C. Black and T. G. Kutateladze, “Atypical Histone Targets of PHD Fingers,” Journal of Biological Chemistry 299, no. 4 (2023): 104601.

[55] M. Ning, T. Hoshii, T. Nakagawa, et al., “Non-catalytic Role of SETD1A Promotes Gastric Cancer Cell Proliferation Through the E2F4-TAF6 Axis in the Cell Cycle,” Cell death & disease 16, no. 1 (2025): 639.

[56] R. J. Separovich and M. R. Wilkins, “Ready, SET, Go: Post-translational Regulation of the Histone Lysine Methylation Network in Budding Yeast,” Journal of Biological Chemistry 297, no. 2 (2021): 100939.

[57] Z. Yang, G. Zhang, R. Zhao, et al., “MLL-AF9 Regulates Transcriptional Initiation in Mixed Lineage Leukemic Cells,” Journal of Biological Chemistry 300, no. 8 (2024): 107566.

[58] B. M. Tibben and S. B. Rothbart, “Mechanisms of DNA Methylation Regulatory Function and Crosstalk With Histone Lysine Methylation,” Journal of Molecular Biology 436, no. 7 (2024): 168394.

[59] G. Zardo, “The Role of H3K4 Trimethylation in CpG Islands Hypermethylation in Cancer,” Biomolecules 11, no. 2 (2021): 143.

[60] W. Rolls, M. D. Wilson, and D. Sproul, “Using human Disease Mutations to Understand De Novo DNA Methyltransferase Function,” Biochemical Society Transactions 52, no. 5 (2024): 2059–2075.

[61] A. Bröhm, T. Schoch, M. Dukatz, et al., “Methylation of Recombinant Mononucleosomes by DNMT3A Demonstrates Efficient Linker DNA Methylation and a Role of H3K36me3,” Communications Biology 5, no. 1 (2022): 192.

[62] H. Hashimoto, P. M. Vertino, and X. Cheng, “Molecular Coupling of DNA Methylation and Histone Methylation,” Epigenomics 2, no. 5 (2010): 657–669.

[63] C. W. Hanna, J. Huang, C. Belton, et al., “Loss of Histone Methyltransferase SETD1B in Oogenesis Results in the Redistribution of Genomic Histone 3 Lysine 4 Trimethylation,” Nucleic Acids Research 50, no. 4 (2022): 1993–2004.

[64] Y. K. Kawamura, E. A. Ozonov, P. Papasaikas, et al., “Preventing CpG Hypermethylation in Oocytes Safeguards Mouse Development,” Developmental Cell 60, no. 23 (2025): 3285–3303.e9.

[65] R. Deplus, B. Delatte, M. K. Schwinn, et al., “TET2 and TET3 Regulate GlcNAcylation and H3K4 Methylation Through OGT and SET1/COMPASS,” Embo Journal 32, no. 5 (2013): 645–655.

[66] D. Gökbuget, L. Goehring, R. M. Boileau, et al., “KMT2C/KMT2D-dependent H3K4me1 Mediates Changes in DNA Replication Timing and Origin Activity During a Cell Fate Transition,” Cell reports 44, no. 2 (2025): 115272.

[67] H. Wang and K. Helin, “Roles of H3K4 Methylation in Biology and Disease,” Trends in Cell Biology 35, no. 2 (2025): 115–128.

[68] J. Zhang, Q. Sun, L. Liu, et al., “Histone methyltransferases MLL2 and SETD1A/B play distinct roles in H3K4me3 deposition during the transition from totipotency to pluripotency,” Embo Journal 44, no. 2 (2025): 437–456.

[69] H. J. Kim, S. J. Moon, S. Hong, et al., “DBC1 is a Key Positive Regulator of Enhancer Epigenomic Writers KMT2D and p300,” Nucleic Acids Research 50, no. 14 (2022): 7873–7888.

[70] T. Hoshii, S. Perlee, S. Kikuchi, et al., “SETD1A regulates Transcriptional Pause Release of Heme Biosynthesis Genes in Leukemia,” Cell Reports 41, no. 9 (2022): 111727.

[71] T. Hoshii, P. Cifani, Z. Feng, et al., “A Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response,” Cell 172, no. 5 (2018): 1007–1021.e17.

[72] H. Liu, S. Takeda, R. Kumar, et al., “Phosphorylation of MLL by ATR Is Required for Execution of Mammalian S-phase Checkpoint,” Nature 467, no. 7313 (2010): 343–346.

[73] S. Chodisetty, A. Arora, K. K. Malik, et al., “MLL/WDR5 complex recruits centriolar satellite protein Cep72 to regulate microtubule nucleation and spindle formation,” Science Advances 10, no. 50 (2024): eadn0086.

[74] Y. Yang, S. Zhang, Z. Wu, et al., “Crystal Structures of Kif2A Complexed With WDR5 Reveal the Structural Plasticity of WIN-S7 Sites,” Acta Biochim Biophys Sin (Shanghai) 57, no. 12 (2025): 1999–2010.

[75] A. Chang, L. Liu, J. M. Ashby, et al., “Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer,” Cancer Research 81, no. 12 (2021): 3358–3373.

[76] K. M. Schüle and S. Probst, “Epigenetic Control of Cell Identities From Epiblast to Gastrulation,” Febs Journal 292, no. 20 (2025): 5259–5287.

[77] C. Meyer, P. Larghero, and B. Almeida Lopes, “The KMT2A Recombinome of Acute Leukemias in 2023,” Leukemia 37, no. 5 (2023): 988–1005.

[78] W. Wang, M. Yang, X. Zhang, et al., “KMT2C/D Mutations in Newly Diagnosed Acute Myeloid Leukaemia: Clinical Features, Genetic co-occurrences and Prognostic Significance,” Clinical and Translational Medicine 15, no. 4 (2025): e70284.

[79] J. Xu, A. Zhong, S. Zhang, et al., “KMT2D Deficiency Promotes Myeloid Leukemias Which Is Vulnerable to Ribosome Biogenesis Inhibition,” Adv Sci (Weinh) 10, no. 19 (2023): e2206098.

[80] J. Ogino and Y. Dou, “Histone Methyltransferase KMT2A: Developmental Regulation to Oncogenic Transformation,” Journal of Biological Chemistry 300, no. 10 (2024): 107791.

[81] H. K. Tsai, C. J. Gibson, H. M. Murdock, et al., “Allelic complexity of KMT2A partial tandem duplications in acute myeloid leukemia and myelodysplastic syndromes,” Blood Adv 6, no. 14 (2022): 4236–4240.

[82] I. G. Cowell and C. A. Austin, “DNA Fragility at the KMT2A/MLL Locus: Insights From Old and New Technologies,” Open Biol 13, no. 1 (Jan 2023): 220232.

[83] Q. Wei, S. Hu, J. Xu, et al., “Detection of KMT2A Partial Tandem Duplication by Optical Genome Mapping in Myeloid Neoplasms: Associated Cytogenetics, Gene Mutations, Treatment Responses, and Patient Outcomes,” Cancers (Basel) 16, no. 24 (2024): 4193.

[84] B. Dai, H. Yu, T. Ma, et al., “The Application of Targeted RNA Sequencing for KMT2A-Partial Tandem Duplication Identification and Integrated Analysis of Molecular Characterization in Acute Myeloid Leukemia,” The Journal of Molecular Diagnostics 23, no. 11 (2021): 1478–1490.

[85] A. Seto, G. Downs, O. King, et al., “Genomic Characterization of Partial Tandem Duplication Involving the KMT2A Gene in Adult Acute Myeloid Leukemia,” Cancers (Basel) 16, no. 9 (2024): 1693.

[86] Q. Li, S. Xing, H. Zhang, et al., “FISH Improves Risk Stratification in Acute Leukemia by Identifying KMT2A Abnormal Copy Number and Rearrangements,” Scientific Reports 12, no. 1 (2022): 9585.

[87] G. C. Issa, J. Zarka, K. Sasaki, et al., “Predictors of Outcomes in Adults With Acute Myeloid Leukemia and KMT2A Rearrangements,” Blood Cancer Journal 11, no. 9 (2021): 162.

[88] L. Yin, L. Wan, Y. Zhang, et al., “Recent Developments and Evolving Therapeutic Strategies in KMT2A-Rearranged Acute Leukemia,” Cancer Medicine 13, no. 20 (2024): e70326.

[89] W. Fiskus, S. Boettcher, N. Daver, et al., “Effective Menin Inhibitor-based Combinations Against AML With MLL Rearrangement or NPM1 Mutation (NPM1c),” Blood Cancer Journal 12, no. 1 (2022): 5.

[90] X. Li and Y. Song, “Structure, Function and Inhibition of Critical Protein-protein Interactions Involving Mixed Lineage Leukemia 1 and Its Fusion Oncoproteins,” Journal of Hematology & Oncology 14, no. 1 (2021): 56.

[91] O. Okeleji, D. McCall, A. Gibson, et al., “Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia,” Blood Advances 9, no. 8 (2025): 1988–1990.

[92] M. Shokoohi, M. Ghaderi, M. Mokarami, et al., “Targeted and Epigenetic Therapies for Acute Myeloid Leukemia Treatment,” Discov Oncology 16, no. 1 (2025): 1711.

[93] M. J. Hochman, J. P. Muniz, and N. Papadantonakis, “Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities,” Journal of Personalized Medicine 15, no. 2 (2025): 49.

[94] A. D. Guarnaccia, K. L. Rose, J. Wang, et al., “mpact of WIN site inhibitor on the WDR5 interactome,” I 34, no. 3 (2021): 108636.

[95] F. Gianni, L. Belver, and A. Ferrando, “The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia,” Cold Spring Harbor Perspectives in Medicine 10, no. 3 (2020): a035246.

[96] J. Stutterheim, I. M. Van der Sluis, K. S. Vrenken, et al., “KMT2A-rearranged Acute Lymphoblastic Leukemia in Infants: Current Progress and Challenges,” Haematologica 110, no. 9 (2025): 1951–1961.

[97] P. Schneider, N. T. Crump, S. Arentsen-Peters, et al., “Modelling Acquired Resistance to DOT1L Inhibition Exhibits the Adaptive Potential of KMT2A-rearranged Acute Lymphoblastic Leukemia,” Experimental Hematology & Oncology 12, no. 1 (2023): 81.

[98] I. M. van der Sluis, P. de Lorenzo, R. S. Kotecha, et al., “Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia,” New England Journal of Medicine 388, no. 17 (2023): 1572–1581.

[99] M. Górecki, I. Kozioł, A. Kopystecka, et al., “Updates in KMT2A Gene Rearrangement in Pediatric Acute Lymphoblastic Leukemia,” Biomedicines 11, no. 3 (2023): 821.

[100] P. Mondello, S. M. Ansell, and G. S. Nowakowski, “Immune Epigenetic Crosstalk Between Malignant B Cells and the Tumor Microenvironment in B Cell Lymphoma,” Frontiers in Genetics 13 (2022): 826594.

[101] R. Niccolai, C. Göbel, and H. Jacobs, “Epigenetically Programmed Identity Crisis to Combat Diffuse Large B Cell Lymphoma,” Trends in Immunology 47, no. 2 (2025): 160–169.

[102] J. Li, C. R. Chin, H. Y. Ying, et al., “Loss of CREBBP and KMT2D Cooperate to Accelerate Lymphomagenesis and Shape the Lymphoma Immune Microenvironment,” Nature Communications 15, no. 1 (2024): 2879.

[103] S. Vlasevska, L. Garcia-Ibanez, R. Duval, et al., “KMT2D acetylation by CREBBP Reveals a Cooperative Functional Interaction at Enhancers in Normal and Malignant Germinal Center B Cells,” Pnas U S A 120, no. 11 (2023): e2218330120.

[104] Y. Jiao, Y. Lv, M. Liu, et al., “The modification role and tumor association with a methyltransferase: KMT2C,” Frontiers in Immunology 15 (2024): 1444923.

[105] C. Liao, W. Huang, M. Lin, et al., “Correlation of KMT2 family Mutations With Molecular Characteristics and Prognosis in Colorectal Cancer,” International Journal of Biological Markers 37, no. 2 (2022): 149–157.

[106] S. Lu, H. S. Kim, Y. Cao, et al., “KMT2D links TGF-β Signaling to Noncanonical Activin Pathway and Regulates Pancreatic Cancer Cell Plasticity,” International Journal of Cancer 153, no. 3 (2023): 552–570.

[107] Z. Yi, S. Wei, and L. Jin, “KDM6A Regulates Cell Plasticity and Pancreatic Cancer Progression by Noncanonical Activin Pathway,” Cell Mol Gastroenterol Hepatol 13, no. 2 (2022): 643–667.

[108] L. Krauß, C. Schneider, E. Hessmann, et al., “Epigenetic Control of Pancreatic Cancer Metastasis,” Cancer and Metastasis Reviews 42, no. 4 (2023): 1113–1131.

[109] M. Li, H. Li, D. Liu, et al., “Analysis of hepatitis B Virus Integration Identifies KMT2B as a Novel Cancer-related Gene in Pancreatic Cancer,” Clinical and Translational Medicine 15, no. 8 (2025): e70424.

[110] M. Anjanappa, Y. Hao, E. R. Simpson, et al., “A System for Detecting High Impact-low Frequency Mutations in Primary Tumors and Metastases,” Oncogene 37, no. 2 (2018): 185–196.

[111] H. Alam, M. Tang, M. Maitituoheti, et al., “KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer,” Cancer Cell 37, no. 4 (2020): 599–617.e7.

[112] Y. Pan, H. Han, H. Hu, et al., “KMT2D deficiency Drives Lung Squamous Cell Carcinoma and Hypersensitivity to RTK-RAS Inhibition,” Cancer Cell 41, no. 1 (2023): 88–105.e8.

[113] J. Qian, S. Zhao, Y. Zou, et al., “Genomic Underpinnings of Tumor Behavior in In Situ and Early Lung Adenocarcinoma,” American Journal of Respiratory and Critical Care Medicine 201, no. 6 (2020): 697–706.

[114] M. Riihimäki, A. Hemminki, M. Fallah, et al., “Metastatic Sites and Survival in Lung Cancer,” Lung Cancer 86, no. 1 (2014): 78–84.

[115] <Periodical>116.</number>M. J. Hoffmann and W. A. Schulz, “Alterations of Chromatin Regulators in the Pathogenesis of Urinary Bladder Urothelial Carcinoma,” Cancers (Basel) 13, no. 23 (2021): 6040.

[116] A. G. Robertson, J. Kim, H. Al-Ahmadie, et al., “Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer,” Cell 174, no. 4 (2018): 1033.

[117] B. Ding, L. Yan, Y. Zhang, et al., “Analysis of the Role of Mutations in the KMT2D Histone Lysine Methyltransferase in Bladder Cancer,” FEBS Open Bio 9, no. 4 (2019): 693–706.

[118] D. Barrows, L. Feng, T. S. Carroll, et al., “Loss of UTX/KDM6A and the Activation of FGFR3 Converge to Regulate Differentiation Gene-expression Programs in Bladder Cancer,” Pnas U S A 117, no. 41 (2020): 25732–25741.

[119] N. Wang, M. R. Pachai, D. Li, et al., “Loss of Kmt2c or Kmt2d Primes Urothelium for Tumorigenesis and Redistributes KMT2A-menin to Bivalent Promoters,” Nature Genetics 57, no. 1 (2025): 165–179.

[120] H. Qiu, V. Makarov, J. K. Bolzenius, et al., “KDM6A Loss Triggers an Epigenetic Switch That Disrupts Urothelial Differentiation and Drives Cell Proliferation in Bladder Cancer,” Cancer Research 83, no. 6 (2023): 814–829.

[121] Y. Xu, Y. Yang, Z. Wang, et al., “ZNF397 Deficiency Triggers TET2-Driven Lineage Plasticity and AR-Targeted Therapy Resistance in Prostate Cancer,” Cancer Discovery 14, no. 8 (2024): 1496–1521.

[122] A. Davies, S. Nouruzi, D. Ganguli, et al., “An Androgen Receptor Switch Underlies Lineage Infidelity in Treatment-resistant Prostate Cancer,” Nature Cell Biology 23, no. 9 (2021): 1023–1034.

[123] T. Limberger, M. Schlederer, K. Trachtová, et al., “KMT2C methyltransferase Domain Regulated INK4A Expression Suppresses Prostate Cancer Metastasis,” Molecular Cancer 21, no. 1 (2022): 89.

[124] H. Cai, B. Zhang, J. Ahrenfeldt, et al., “CRISPR/Cas9 Model of Prostate Cancer Identifies Kmt2c Deficiency as a Metastatic Driver by Odam/Cabs1 Gene Cluster Expression,” Nature Communications 15, no. 1 (2024): 2088.

[125] S. Zhu, N. Xu, J. Liang, et al., “Mutations in Epigenetic Regulator KMT2C Detected by Liquid Biopsy Are Associated With Worse Survival in Prostate Cancer Patients,” Oncology Research 31, no. 4 (2023): 605–614.

[126] K. Gala, Q. Li, A. Sinha, et al., “KMT2C mediates the Estrogen Dependence of Breast Cancer Through Regulation of ERα Enhancer Function,” Oncogene 37, no. 34 (2018): 4692–4710.

[127] K. M. Jozwik, I. Chernukhin, A. A. Serandour, et al., “FOXA1 Directs H3K4 Monomethylation at Enhancers via Recruitment of the Methyltransferase MLL3,” Cell Reports 17, no. 10 (2016): 2715–2723.

[128] M. Seehawer, Z. Li, J. Nishida, et al., “Loss of Kmt2c or Kmt2d Drives Brain Metastasis via KDM6A-dependent Upregulation of MMP3,” Nature Cell Biology 26, no. 7 (2024): 1165–1175.

[129] A. Jarratt, J. Polidano, C. L. Scott, et al., “Genomics of Ovarian Cancers and the Potential of Precision Medicine,” Therapeutic Advances in Medical Oncology 17 (2025): 17588359251396651.

[130] N. Dedes, M. Liontos, D. Haidopoulos, et al., “Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives,” Biomedicines 13, no. 11 (2025): 2820.

[131] D. Oliveira, T. H. Schnack, T. S. Poulsen, et al., “Genomic Sub-Classification of Ovarian Clear Cell Carcinoma Revealed by Distinct Mutational Signatures,” Cancers (Basel) 13, no. 20 (2021): 5242.

[132] M. Gan, Z. Tai, Y. Yu, et al., “Next-generation Sequencing Shows the Genomic Features of Ovarian Clear Cell Cancer and Compares the Genetic Architectures of High-grade Serous Ovarian Cancer and Clear Cell Carcinoma in Ovarian and Endometrial Tissues,” PeerJ 11 (2023): e14653.

[133] H. Chai, C. Pan, M. Zhang, et al., “Histone methyltransferase SETD1A interacts with notch and promotes notch transactivation to augment ovarian cancer development,” BMC cancer 23, no. 1 (2023): 96.

[134] Y. Zhu, S. Jiang, R. Tang, et al., “KMT2A facilitates the Epithelial-to-mesenchymal Transition and the Progression of Ovarian Cancer,” Molecular and Cellular Biochemistry 480, no. 5 (2025): 3001–3017.

[135] S. da G. F. Carvalho, C. M. de Gusmão, et al., “Methylation Assay in KMT2B-related Dystonia: A Novel Diagnostic Validation Tool,” Clin Epigenetics 16, no. 1 (2024): 169.

[136] L. Cif, D. Demailly, J. P. Lin, et al., “KMT2B-related Disorders: Expansion of the Phenotypic Spectrum and Long-term Efficacy of Deep Brain Stimulation,” Brain 143, no. 11 (2020): 3242–3261.

[137] M. Abel, R. Pfister, I. Hussein, et al., “Deep Brain Stimulation in KMT2B-Related Dystonia: Case Report and Review of the Literature with Special Emphasis on Dysarthria and Speech,” Frontiers of Neurology 12 (2021): 662910.

[138] R. Rajan, K. Garg, A. Saini, et al., “GPi-DBS for KMT2B-Associated Dystonia: Systematic Review and Meta-Analysis,” Movement Disorders Clinical Practice 9, no. 1 (2022): 31–37.

[139] K. Oexle, M. Zech, L. G. Stühn, et al., “Episignature Analysis of Moderate Effects and Mosaics,” European Journal of Human Genetics 31, no. 9 (2023): 1032–1039.

[140] S. Boniel, K. Szymańska, R. Śmigiel, et al., “Kabuki Syndrome-Clinical Review With Molecular Aspects,” Genes 12, no. 4 (2021): 468.

[141] S. Boniel, M. Krajewska, B. Pyrżak, et al., “Clinical and molecular characteristics of Kabuki syndrome patients with missense variants-novel features and literature review,” Frontiers in Genetics 15 (2024): 1402531.

[142] K. K. Barry, M. Tsaparlis, D. Hoffman, et al., “From Genotype to Phenotype-A Review of Kabuki Syndrome,” Genes 13, no. 10 (2022): 1761.

[143] V. Faundes, S. Goh, R. Akilapa, et al., “Clinical Delineation, Sex Differences, and Genotype-phenotype Correlation in Pathogenic KDM6A Variants Causing X-linked Kabuki Syndrome Type 2,” Genetics in Medicine 23, no. 7 (2021): 1202–1210.

[144] M. Jefri, X. Zhang, P. S. Stumpf, et al., “Kabuki syndrome Stem Cell Models Reveal Locus Specificity of Histone Methyltransferase 2D (KMT2D/MLL4),” Human Molecular Genetics 31, no. 21 (2022): 3715–3728.

[145] C. S. Golden, S. Williams, and M. A. Serrano, “Molecular insights of KMT2D and clinical aspects of Kabuki syndrome type 1,” Birth Defects Res 115, no. 19 (2023): 1809–1824.

[146] Z. Shan, Y. Zhao, X. Chen, et al., “KMT2D deficiency Leads to Cellular Developmental Disorders and Enhancer Dysregulation in Neural-crest-containing Brain Organoids,” Sci Bull (Beijing) 69, no. 22 (2024): 3533–3546.

[147] L. Khalife, R. Gottlieb, T. Daly, et al., “Multidisciplinary clinical and translational approach for optimizing management for complex and rare conditions using Kabuki syndrome as example,” Rare 2023; 1:100008.

[148] R. Nardello, G. D. Mangano, A. Fontana, et al., “Broad Neurodevelopmental Features and Cortical Anomalies Associated With a Novel De Novo KMT2A Variant in Wiedemann-Steiner Syndrome,” Eur J Med Genet 64, no. 2 (2021): 104133.

[149] Y. Lin, X. Chen, B. Xie, et al., “Novel variants and phenotypic heterogeneity in a cohort of 11 Chinese children with Wiedemann-Steiner syndrome,” Frontiers in Genetics 14 (2023): 1085210.

[150] C. N. Vallianatos, B. Raines, R. S. Porter, et al., “Mutually Suppressive Roles of KMT2A and KDM5C in Behaviour, Neuronal Structure, and Histone H3K4 Methylation,” Communications Biology 3, no. 1 (2020): 278.

[151] M. Wang, J. Hu, Z. Zhang, et al., “Diagnosis and recombinant human growth hormone treatment of Wiedemann-Steiner syndrome: Discovery of novel KMT2A variants and review of existing literature,” BMC Pediatrics [Electronic Resource] 25, no. 1 (2025): 523.

[152] L. Yang, M. Jin, and K. W. Jeong, “Histone H3K4 Methyltransferases as Targets for Drug-Resistant Cancers,” Biology (Basel) 10, no. 7 (2021): 581.

[153] R. J. Fagan and A. K. Dingwall, “COMPASS Ascending: Emerging Clues Regarding the Roles of MLL3/KMT2C and MLL2/KMT2D Proteins in Cancer,” Cancer Letters 458 (2019): 56–65.

[154] J. Schwenty-Lara, D. Nehl, and A. Borchers, “The Histone Methyltransferase KMT2D, Mutated in Kabuki syndrome Patients, Is Required for Neural Crest Cell Formation and Migration,” Human Molecular Genetics 29, no. 2 (2020): 305–319.

[155] J. Zhu, Z. Liu, X. Liang, et al., “A Pan-Cancer Study of KMT2 Family as Therapeutic Targets in Cancer,” Journal of Oncology 2022 (2022): 3982226.

[156] J. B. Dawkins, J. Wang, E. Maniati, et al., “Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates With Improved Outcome in Pancreatic Ductal Adenocarcinoma,” Cancer Research 76, no. 16 (2016): 4861–4871.

[157] P. Sun, T. Wu, X. Sun, et al., “KMT2D inhibits the Growth and Metastasis of Bladder Cancer Cells by Maintaining the Tumor Suppressor Genes,” Biomedicine & Pharmacotherapy 115 (2019): 108924.

[158] S. Castiglioni, E. Di Fede, C. Bernardelli, et al., “KMT2A: Umbrella Gene for Multiple Diseases,” Genes (Basel) 13, no. 3 (2022): 514.

[159] D. X. Wang, J. Y. Long, R. Z. Li, et al., “Mutation Status of the KMT2 family Associated With Immune Checkpoint Inhibitors (ICIs) Therapy and Implicating Diverse Tumor Microenvironments,” Molecular Cancer 23, no. 1 (2024): 15.

[160] P. Zhang and Y. Huang, “Genomic Alterations in KMT2 family Predict Outcome of Immune Checkpoint Therapy in Multiple Cancers,” Journal of Hematology & Oncology 14, no. 1 (2021): 39.

[161] G. Wang, R. D. Chow, L. Zhu, et al., “CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade,” Cancer discovery 10, no. 12 (2020): 1912–1933.

[162] R. M. Chabanon, M. Pedrero, C. Lefebvre, et al., “Mutational Landscape and Sensitivity to Immune Checkpoint Blockers,” Clinical Cancer Research 22, no. 17 (2016): 4309–4321.

[163] D. A. Arber, A. Orazi, R. Hasserjian, et al., “The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia,” Blood 127, no. 20 (2016): 2391–2405.

[164] C. Meyer, T. Burmeister, D. Gröger, et al., “The MLL Recombinome of Acute Leukemias in 2017,” Leukemia 32, no. 2 (2018): 273–284.

[165] R. E. van Weelderen, C. J. Harrison, K. Klein, et al., “Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia,” Blood Advance 8, no. 12 (2024): 3200–3213.

[166] A. J. S. Chan, C. Cytrynbaum, N. Hoang, et al., “Expanding the Neurodevelopmental Phenotypes of Individuals With De Novo KMT2A Variants,” Nature Partner Journals Genomic Medicine 4 (2019): 9.

[167] J. Min Ko, J. S. Cho, and Y. Yoo, “Wiedemann-Steiner Syndrome with 2 Novel KMT2A Mutations,” Journal of Child Neurology 32, no. 2 (2017): 237–242.

[168] S. Luo, B. Bi, W. Zhang, et al., “Three De Novo Variants in KMT2A (MLL) Identified by Whole Exome Sequencing in Patients With Wiedemann-Steiner Syndrome,” Molecular Genetics & Genomic Medicine 9, no. 10 (2021): e1798.

[169] E. Meyer, K. J. Carss, J. Rankin, et al., “Mutations in the Histone Methyltransferase Gene KMT2B Cause Complex Early-onset Dystonia,” Nature Genetics 49, no. 2 (2017): 223–237.

[170] M. Zech, S. Boesch, E. M. Maier, et al., “Haploinsufficiency of KMT2B, Encoding the Lysine-Specific Histone Methyltransferase 2B, Results in Early-Onset Generalized Dystonia,” American Journal of Human Genetics 99, no. 6 (2016): 1377–1387.

[171] A. Ciolfi, A. Foroutan, A. Capuano, et al., “Childhood-onset Dystonia-causing KMT2B Variants Result in a Distinctive Genomic Hypermethylation Profile,” Clin Epigenetics 13, no. 1 (2021): 157.

[172] T. S. Koemans, T. Kleefstra, M. C. Chubak, et al., “Functional Convergence of Histone Methyltransferases EHMT1 and KMT2C Involved in Intellectual Disability and Autism Spectrum Disorder,” Plos Genetics 13, no. 10 (2017): e1006864.

[173] T. Kleefstra, J. M. Kramer, K. Neveling, et al., “Disruption of an EHMT1-associated Chromatin-modification Module Causes Intellectual Disability,” American Journal of Human Genetics 91, no. 1 (2012): 73–82.

[174] M. Frega, M. Selten, B. Mossink, et al., “Distinct Pathogenic Genes Causing Intellectual Disability and Autism Exhibit a Common Neuronal Network Hyperactivity Phenotype,” Cell reports 30, no. 1 (2020): 173–186.

[175] V. Faundes, W. G. Newman, L. Bernardini, et al., “Histone Lysine Methylases and Demethylases in the Landscape of Human Developmental Disorders,” American Journal of Human Genetics 102, no. 1 (2018): 175–187.

[176] X. Hu, A. Biswas, and S. De, “KMT2C-deficient tumors have elevated APOBEC mutagenesis and genomic instability in multiple cancers,” NAR Cancer 2022; 4(3):zcac023.

[177] M. P. Adam, S. Banka, H. T. Bjornsson, et al., “Kabuki Syndrome: International Consensus Diagnostic Criteria,” Journal of Medical Genetics 56, no. 2 (2019): 89–95.

[178] Y. Kuroki, Y. Suzuki, H. Chyo, et al., “A New Malformation Syndrome of Long Palpebral Fissures, Large Ears, Depressed Nasal Tip, and Skeletal Anomalies Associated With Postnatal Dwarfism and Mental Retardation,” Journal of Pediatrics 99, no. 4 (1981): 570–573.

[179] S. B. Ng, A. W. Bigham, K. J. Buckingham, et al., “Exome Sequencing Identifies MLL2 Mutations as a Cause of Kabuki Syndrome,” Nature Genetics 42, no. 9 (2010): 790–793.

[180] S. S. Dhar and M. G. Lee, “Cancer-epigenetic Function of the Histone Methyltransferase KMT2D and Therapeutic Opportunities for the Treatment of KMT2D-deficient Tumors,” Oncotarget 12, no. 13 (2021): 1296–1308.

[181] J. Kummeling, D. E. Stremmelaar, N. Raun, et al., “Characterization of SETD1A haploinsufficiency in humans and Drosophila defines a novel neurodevelopmental syndrome,” Molecular Psychiatry 26, no. 6 (2021): 2013–2024.

[182] A. Takata, B. Xu, I. Ionita-Laza, et al., “Loss-of-function Variants in Schizophrenia Risk and SETD1A as a Candidate Susceptibility Gene,” Neuron 82, no. 4 (2014): 773–780.

[183] A. Takata, I. Ionita-Laza, J. A. Gogos, et al., “De Novo Synonymous Mutations in Regulatory Elements Contribute to the Genetic Etiology of Autism and Schizophrenia,” Neuron 89, no. 5 (2016): 940–947.

[184] T. Singh, M. I. Kurki, D. Curtis, et al., “Rare Loss-of-function Variants in SETD1A Are Associated With Schizophrenia and Developmental Disorders,” Nature Neuroscience 19, no. 4 (2016): 571–577.

[185] R. Birnbaum and D. R. Weinberger, “Genetic Insights Into the Neurodevelopmental Origins of Schizophrenia,” Nature Reviews Neuroscience 18, no. 12 (2017): 727–740.

[186] I. M. Krzyzewska, S. M. Maas, P. Henneman, et al., “A Genome-wide DNA Methylation Signature for SETD1B-related Syndrome,” Clin Epigenetics 11, no. 1 (2019): 156.

[187] A. Roston, D. Evans, H. Gill, et al., “SETD1B-associated Neurodevelopmental Disorder,” Journal of Medical Genetics 58, no. 3 (Mar 2021): 196–204.

[188] T. Hiraide, M. Nakashima, K. Yamoto, et al., “De Novo Variants in SETD1B Are Associated With Intellectual Disability, Epilepsy and Autism,” Human Genetics 137, no. 1 (2018): 95–104.

[189] T. Hiraide, A. Hattori, D. Ieda, et al., “De Novo Variants in SETD1B Cause Intellectual Disability, Autism Spectrum Disorder, and Epilepsy With Myoclonic Absences,” Epilepsia Open 4, no. 3 (2019): 476–481.

[190] C. Roth, H. Kilpinen, M. A. Kurian, et al., “Histone Lysine Methyltransferase-related Neurodevelopmental Disorders: Current Knowledge and saRNA Future Therapies,” Frontiers in Cell and Developmental Biology 11 (2023): 1090046.

[191] A. Zucenka, G. C. Issa, M. Arellano, et al., “Revumenib Maintenance Therapy Following Revumenib-Induced Remission an d Transplant,” Blood 142, no. Supplement 1 (2023): 4950–4950.

[192] H. P. Erba, A. T. Fathi, G. C. Issa, et al., “Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) in Hibitor Ziftomenib (KO-539) in Patients With Relapsed or Refractory Ac Ute Myeloid Leukemia,” Blood 140, no. Supplement 1 (2022): 153–156.

[193] E. S. Wang, G. C. Issa, H. P. Erba, et al., “Ziftomenib in Relapsed or Refractory Acute Myeloid Leukaemia (KOMET-001): A Multicentre, Open-label, Multi-cohort, Phase 1 Trial,” The Lancet Oncology 25, no. 10 (Oct 2024): 1310–1324.

[194] E. Jabbour, E. Searle, and M. Abdul-Hay, “A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients With Relapsed/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations,” Blood 142, no. Supplement 1 (2023): 57–57.

[195] J. Lancet, F. Ravandi, P. Montesinos, et al., “Covalent Menin Inhibitor Bmf-219 in Patients With Relapsed or Refracto Ry (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data From the Covale Nt-101 Study,” Blood 142, no. Supplement 1 (2023): 2916–2916.

[196] J. F. Zeidner, J. Yuda, J. M. Watts, et al., “Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhib Itor Enzomenib (DSP-5336) in Patients With Relapsed or Refractory Acut e Leukemia,” Blood 144, no. Supplement 1 (2024): 213–213.

[197] D. Wu, Y. Wang, S. Chen, et al., “A First-in-Human Phase 1/2 Study of the Menin-KMT2A(MLL1) Inhibitor BN 104 in Adult Patients With Relapsed or Refractory Acute Leukemia,” Blood 144, no. Supplement 1 (2024): 2879–2879.

[198] N. Shukla, C. Wetmore, and M. M. O'Brien, “Final Report of Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EP Z-5676), in Children With Relapsed or Refractory MLL-r Acute Leukemia,” Blood 128, no. 22 (2016): 2780–2780.

[199] E. M. Stein, G. Garcia-Manero, D. A. Rizzieri, et al., “The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia,” Blood 131, no. 24 (2018): 2661–2669.

[200] O. Salamero, P. Montesinos, C. Willekens, et al., “First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia,” Journal of Clinical Oncology 38, no. 36 (2020): 4260–4273.

[201] G. C. Issa, A. J. Ambinder, and W. Xiao, “A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib (Trial In Progress),” Blood 144, no. Supplement 1 (2024): 4265.2–4265.2.

[202] G. C. Issa, B. Cuglievan, N. Daver, et al., “Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) With Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AM L,” Blood 144, no. Supplement 1 (2024): 216–216.

[203] J. F. Zeidner, T. L. Lin, R. L. Welkie, et al., “Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML,” Journal of Clinical Oncology 43, no. 23 (2025): 2606–2615.

[204] U. Borate, J. Jain, Y. Huang, et al., “Preliminary Results of a Phase 1 Study of the Safety and Tolerability of the Combination of revumenib (REV) With gilteritinib (GILT) in Rela psed/Refractory (R/R) Acute Myeloid Leukemia (AML),” Blood 146, no. Supplement 1 (2025): 3427–3427.

[205] Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML. 2025;

[206] G. Issa, A. Fathi, A. Zeidan, et al., “Ziftomenib in Combination With Venetoclax and Azacitidine in Relapsed/Refractory NPM1-m or KMT2A-r Acute Myeloid Leukemia: Updated Phase 1a/ b Safety and Clinical Activity Results From KOMET-007,” Blood 146, no. Supplement 1 (2025): 764–764.

[207] D. McCall, B. Cuglievan, A. Gibson, et al., “A Phase I Study Investigating the Combination of the Ziftomenib, Venet Oclax and Azacitidine (ZiVA) in Pediatric Relapsed and Refractory Acut E Leukemias,” Blood 144, no. Supplement 1 (2024): 1504.4–1504.4.

[208] E. Salzer, J. Stutterheim, B. Cuglievan, et al., “APAL2020K/ITCC-101: A Phase I Trial of the Menin Inhibitor Ziftomenib in Combination With Chemotherapy in Children With Relapsed/Refractory KMT2A-rearranged, NUP98-rearranged, or NPM1-mutant Acute Leukemias,” Blood 144, no. Supplement 1 (2024): 4265.3–4265.3.

[209] C. Recher, J. O'Nions, and I. Aldoss, “Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia With KMT2Ar or NPM1 Alterations,” Blood 144, no. Supplement 1 (2024): 215–215.

[210] K. Menghrajani, S. F. Cai, S. M. Devlin, et al., “A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinomet Ostat in Combination With Azacitidine in Patients With 11q23-Rearrange D Acute Myeloid Leukemia,” Blood 134, no. Supplement_1 (2019): 2655–2655.

[211] P. A. Brown, J. A. Kairalla, J. M. Hilden, et al., “FLT3 inhibitor lestaurtinib plus Chemotherapy for Newly Diagnosed KMT2A-rearranged Infant Acute Lymphoblastic Leukemia: Children's Oncology Group Trial AALL0631,” Leukemia 35, no. 5 (2021): 1279–1290.

[212] R. Pieters, P. De Lorenzo, P. Ancliffe, et al., “Outcome of Infants Younger than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol: Results from an International Phase III Randomized Study,” Journal of Clinical Oncology 37, no. 25 (2019): 2246–2256.

[213] T. M. Cooper, J. Cassar, E. Eckroth, et al., “A Phase I Study of Quizartinib Combined With Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study,” Clinical Cancer Research 22, no. 16 (2016): 4014–4022.

[214] Y. M. Soto-Feliciano, F. J. Sánchez-Rivera, F. Perner, et al., “A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition,” Cancer discovery 13, no. 1 (2023): 146–169.

[215] S. Dhiman, V. Dhillon, and S. K. Balasubramanian, “Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions,” Cancers (Basel) 16, no. 22 (2024): 3743.

[216] G. Cao, H. Zhang, S. Sun, et al., “Menin Inhibitors From Monotherapies to Combination Therapies: Clinical Trial Updates From 2024 ASH Annual Meeting,” Journal of hematology & oncology 18, no. 1 (2025): 63.

[217] P. Niscola, V. Gianfelici, M. Giovannini, et al., “Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias,” Cancers (Basel) 17, no. 1 (2025): 142.

[218] X. Thomas, “Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation,” Oncology Therapy 12, no. 1 (2024): 57–72.

[219] Y. Y. Syed, “Revumenib: First Approval,” Drugs 85, no. 4 (2025): 577–583.

[220] M. L. Arellano, M. J. Thirman, J. F. DiPersio, et al., “Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study,” Blood 146, no. 9 (2025): 1065–1077.

[221] W. Fiskus, N. Daver, S. Boettcher, et al., “Activity of Menin Inhibitor ziftomenib (KO-539) as Monotherapy or in Combinations Against AML Cells With MLL1 Rearrangement or Mutant NPM1,” Leukemia 36, no. 11 (2022): 2729–2733.

[222] J. Rausch, M. M. Dzama, N. Dolgikh, et al., “Menin Inhibitor ziftomenib (KO-539) Synergizes With Drugs Targeting Chromatin Regulation or Apoptosis and Sensitizes Acute Myeloid Leukemia With MLL Rearrangement or NPM1 Mutation to Venetoclax,” Haematologica 108, no. 10 (2023): 2837–2843.

[223] E. S. Wang, P. Montesinos, J. Foran, et al., “Ziftomenib in Relapsed or Refractory NPM1-Mutated AML,” Journal of Clinical Oncology 43, no. 31 (2025): 3381–3390.

[224] H. Erba, E. Wang, G. Issa, et al., “AML-475 Activity, Tolerability, and Resistance Profile of the Menin in Hibitor Ziftomenib in Adults with Relapsed/Refractory NPM1-Mutated AML,” Clinical Lymphoma Myeloma and Leukemia 23 (2023): S304–S305.

[225] K. Lu, H. Tao, X. Si, et al., “The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer,” Frontiers in oncology 8 (2018): 502.

[226] M. Getlik, D. Smil, C. Zepeda-Velázquez, et al., “Structure-Based Optimization of a Small Molecule Antagonist of the Interaction between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1),” Journal of Medicinal Chemistry 59, no. 6 (2016): 2478–2496.

[227] M. Zhang, M. Chen, P. Li, et al., “Therapeutic Targeting of WDR5-MLL1 by EMBOW-derived Peptides Suppresses Leukemia Progression,” Cell Chemistry & Biology 32, no. 11 (2025): 1353–1366.e6.

[228] H. Karatas, E. C. Townsend, F. Cao, et al., “High-affinity, Small-molecule Peptidomimetic Inhibitors of MLL1/WDR5 Protein-protein Interaction,” Journal of the American Chemical Society 135, no. 2 (2013): 669–682.

[229] F. Cao, E. C. Townsend, H. Karatas, et al., “Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-lineage Leukemia,” Molecular Cell 53, no. 2 (2014): 247–261.

[230] F. Wang, K. O. Jeon, J. M. Salovich, et al., “Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]Imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design,” Journal of Medicinal Chemistry 61, no. 13 (2018): 5623–5642.

[231] J. Cao, T. Fan, Y. Li, et al., “Phage-Display Based Discovery and Characterization of Peptide Ligands against WDR5,” Molecules (Basel, Switzerland) 26, no. 5 (2021): 1225.

[232] M. Schapira, M. Tyers, M. Torrent, et al., “WD40 repeat Domain Proteins: A Novel Target Class?,” Nature Reviews Drug Discovery 16, no. 11 (2017): 773–786.

[233] F. Grebien, M. Vedadi, M. Getlik, et al., “Pharmacological Targeting of the Wdr5-MLL Interaction in C/EBPα N-terminal Leukemia,” Nature Chemical Biology 11, no. 8 (2015): 571–578.

[234] J. Zhu, M. A. Sammons, G. Donahue, et al., “Gain-of-function p53 Mutants co-opt Chromatin Pathways to Drive Cancer Growth,” Nature 525, no. 7568 (2015): 206–211.

[235] X. Peng, Z. Hu, L. Zeng, et al., “Overview of Epigenetic Degraders Based on PROTAC, Molecular Glue, and Hydrophobic Tagging Technologies,” Acta Pharm Sin B 14, no. 2 (2024): 533–578.

[236] G. Zhang, J. Zhang, Y. Gao, et al., “Strategies for Targeting Undruggable Targets,” Expert Opinion on Drug Discovery 17, no. 1 (2022): 55–69.

[237] H. Wu, H. Yao, C. He, et al., “Molecular Glues Modulate Protein Functions by Inducing Protein Aggregation: A Promising Therapeutic Strategy of Small Molecules for Disease Treatment,” Acta Pharm Sin B 12, no. 9 (Sep 2022): 3548–3566.

[238] X. Yu, D. Li, J. Kottur, et al., “A Selective WDR5 Degrader Inhibits Acute Myeloid Leukemia in Patient-derived Mouse Models,” Science Translational Medicine 13, no. 613 (2021): eabj1578.

[239] A. Dölle, B. Adhikari, A. Krämer, et al., “Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders,” Journal of Medicinal Chemistry 64, no. 15 (2021): 10682–10710.

[240] D. Li, X. Yu, J. Kottur, et al., “Discovery of a Dual WDR5 and Ikaros PROTAC Degrader as an Anti-cancer Therapeutic,” Oncogene 41, no. 24 (2022): 3328–3340.

[241] L. Wan, H. Wen, Y. Li, et al., “ENL Links Histone Acetylation to Oncogenic Gene Expression in Acute Myeloid Leukaemia,” Nature 543, no. 7644 (2017): 265–269.

[242] A. V. Krivtsov and S. A. Armstrong, “MLL Translocations, Histone Modifications and Leukaemia Stem-cell Development,” Nature Reviews Cancer 7, no. 11 (2007): 823–833.

[243] L. Garnar-Wortzel, T. R. Bishop, S. Kitamura, et al., “Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia,” ACS Cent Sci 7, no. 5 (2021): 815–830.

[244] X. Li, Y. Yao, F. Wu, et al., “A Proteolysis-targeting Chimera Molecule Selectively Degrades ENL and Inhibits Malignant Gene Expression and Tumor Growth,” Journal of Hematology & Oncology 15, no. 1 (2022): 41.

[245] E. Alexandrova, A. Salvati, G. Pecoraro, et al., “Histone Methyltransferase DOT1L as a Promising Epigenetic Target for Treatment of Solid Tumors,” Frontiers in Genetics 13 (2022): 864612.

[246] H. Tang, Y. F. Lu, R. Zeng, et al., “DOT1L-mediated RAP80 Methylation Promotes BRCA1 Recruitment to Elicit DNA Repair,” Pnas U S A 121, no. 35 (2024): e2320804121.

[247] L. Jinfeng, P. Shengfei, W. Dongxue, et al., “Inhibition of Methyltransferase DOT1L Alleviates Anti-tuberculosis Drug-induced Liver Injury by Inhibiting p53-Bax/Bcl-2 Pathway,” European Journal of Pharmacology 1010 (2026): 178415.

[248] M. Mecca, S. Picerno, and S. Cortellino, “The Killer's Web: Interconnection Between Inflammation, Epigenetics and Nutrition in Cancer,” International Journal of Molecular Sciences 25, no. 5 (2024): 2750.

[249] M. Karsa, E. Ronca, A. Bongers, et al., “Systematic in Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia,” Frontiers in Oncology 11 (2021): 779859.

[250] G. S. Gibbons, A. Chakraborty, S. M. Grigsby, et al., “Identification of DOT1L Inhibitors by Structure-based Virtual Screening Adapted From a Nucleoside-focused Library,” European Journal of Medicinal Chemistry 189 (2020): 112023.

[251] J. P. Loftus, A. Yahiaoui, P. A. Brown, et al., “Combinatorial Efficacy of Entospletinib and Chemotherapy in Patient-derived Xenograft Models of Infant Acute Lymphoblastic Leukemia,” Haematologica 106, no. 4 (2021): 1067–1078.

[252] N. J. Waters, “Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L,” European Journal of Drug Metabolism and Pharmacokinetics 42, no. 6 (2017): 891–901.

[253] R. A. Copeland, “Protein Methyltransferase Inhibitors as Precision Cancer Therapeutics: A Decade of Discovery,” Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences 373 (2018): 20170080.

[254] C. W. Chen and S. A. Armstrong, “Targeting DOT1L and HOX Gene Expression in MLL-rearranged Leukemia and Beyond,” Experimental Hematology 43, no. 8 (2015): 673–684.

[255] C. W. Chen, R. P. Koche, A. U. Sinha, et al., “DOT1L inhibits SIRT1-mediated Epigenetic Silencing to Maintain Leukemic Gene Expression in MLL-rearranged Leukemia,” Nature Medicine 21, no. 4 (2015): 335–343.

[256] S. Wright, J. Hu, H. Wang, et al., “Interrogating Bromodomain Inhibitor Resistance in KMT2A-rearranged Leukemia Through Combinatorial CRISPR Screens,” PNAS 120, no. 16 (2023): e2220134120.

[257] J. D. Brown, Z. B. Feldman, S. P. Doherty, et al., “BET Bromodomain Proteins Regulate Enhancer Function During Adipogenesis,” Pnas U S A 115, no. 9 (2018): 2144–2149.

[258] L. Guo, J. Li, H. Zeng, et al., “A Combination Strategy Targeting Enhancer Plasticity Exerts Synergistic Lethality Against BETi-resistant Leukemia Cells,” Nature Communications 11, no. 1 (2020): 740.

[259] M. A. Dawson, R. K. Prinjha, A. Dittmann, et al., “Inhibition of BET Recruitment to Chromatin as an Effective Treatment for MLL-fusion Leukaemia,” Nature 478, no. 7370 (2011): 529–533.

[260] J. Zuber, J. Shi, E. Wang, et al., “RNAi Screen Identifies Brd4 as a Therapeutic Target in Acute Myeloid Leukaemia,” Nature 478, no. 7370 (2011): 524–528.

[261] O. Gilan, I. Rioja, K. Knezevic, et al., “Selective Targeting of BD1 and BD2 of the BET Proteins in Cancer and Immunoinflammation,” Science 368, no. 6489 (2020): 387–394.

[262] E. J. Faivre, K. F. McDaniel, D. H. Albert, et al., “Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer,” Nature 578, no. 7794 (2020): 306–310.

[263] P. Rathert, M. Roth, T. Neumann, et al., “Transcriptional Plasticity Promotes Primary and Acquired Resistance to BET Inhibition,” Nature 525, no. 7570 (2015): 543–547.

[264] G. Boysen, C. E. Barbieri, D. Prandi, et al., “SPOP Mutation Leads to Genomic Instability in Prostate Cancer,” Elife 4 (2015): e09207.

[265] M. Blattner, D. J. Lee, and C. O'Reilly, “SPOP Mutations in Prostate Cancer Across Demographically Diverse Patient Cohorts,” Neoplasia 16, no. 1 (2014): 14–20.

[266] C. E. Barbieri, S. C. Baca, M. S. Lawrence, et al., “Exome Sequencing Identifies Recurrent SPOP, FOXA1 and MED12 Mutations in Prostate Cancer,” Nature Genetics 44, no. 6 (2012): 685–689.

[267] M. S. Ostertag, W. Hutwelker, O. Plettenburg, et al., “Structural Insights Into BET Client Recognition of Endometrial and Prostate Cancer-Associated SPOP Mutants,” Journal of Molecular Biology 431, no. 11 (2019): 2213–2221.

[268] H. Janouskova, G. El Tekle, E. Bellini, et al., “Opposing Effects of Cancer-type-specific SPOP Mutants on BET Protein Degradation and Sensitivity to BET Inhibitors,” Nature Medicine 23, no. 9 (2017): 1046–1054.

[269] C. Zeng, Y. Wang, Q. Lu, et al., “SPOP Suppresses Tumorigenesis by Regulating Hedgehog/Gli2 Signaling Pathway in Gastric Cancer,” Journal of Experimental & Clinical Cancer Research 33, no. 1 (2014): 75.

[270] X. Dai, W. Gan, X. Li, et al., “Prostate Cancer-associated SPOP Mutations Confer Resistance to BET Inhibitors Through Stabilization of BRD4,” Nature Medicine 23, no. 9 (2017): 1063–1071.

[271] Y. Fang, G. Liao, and B. Yu, “LSD1/KDM1A inhibitors in Clinical Trials: Advances and Prospects,” Journal of hematology & oncology 12, no. 1 (2019): 129.

[272] G. J. Yang, P. M. Lei, S. Y. Wong, et al., “Pharmacological Inhibition of LSD1 for Cancer Treatment,” Molecules (Basel, Switzerland) 23, no. 12 (2018): 3194.

[273] D. D. Shen, J. R. Pang, Y. P. Bi, et al., “LSD1 deletion Decreases Exosomal PD-L1 and Restores T-cell Response in Gastric Cancer,” Molecular Cancer 21, no. 1 (2022): 75.

[274] A. Kumaraswamy, Z. Duan, D. Flores, et al., “LSD1 promotes Prostate Cancer Reprogramming by Repressing TP53 Signaling Independently of Its Demethylase Function,” JCI Insight 8, no. 15 (2023): e167440.

[275] K. Chen, Y. Cai, C. Cheng, et al., “MYT1 attenuates neuroblastoma cell differentiation by interacting with the LSD1/CoREST complex,” Oncogene 39, no. 21 (2020): 4212–4226.

[276] S. Xu, L. Zheng, L. Kang, et al., “microRNA-let-7e in Serum-derived Exosomes Inhibits the Metastasis of Non-small-cell Lung Cancer in a SUV39H2/LSD1/CDH1-dependent Manner,” Cancer Gene Therapy 28, no. 3-4 (2021): 250–264.

[277] S. D. Briggs, M. Bryk, B. D. Strahl, et al., “Histone H3 Lysine 4 Methylation Is Mediated by Set1 and Required for Cell Growth and rDNA Silencing in Saccharomyces Cerevisiae,” Genes & Development 15, no. 24 (2001): 3286–3295.

[278] W. J. Harris, X. Huang, J. T. Lynch, et al., “The Histone Demethylase KDM1A Sustains the Oncogenic Potential of MLL-AF9 Leukemia Stem Cells,” Cancer Cell 21, no. 4 (2012): 473–847.

[279] B. Noce, E. Di Bello, R. Fioravanti, et al., “LSD1 inhibitors for Cancer Treatment: Focus on Multi-target Agents and Compounds in Clinical Trials,” Frontiers in pharmacology 14 (2023): 1120911.

[280] S. Baby, S. D. Shinde, N. Kulkarni, et al., “Lysine-Specific Demethylase 1 (LSD1) Inhibitors: Peptides as an Emerging Class of Therapeutics,” Acs Chemical Biology 18, no. 10 (2023): 2144–2155.

[281] X. J. Dai, Y. Liu, X. P. Xiong, et al., “Tranylcypromine Based Lysine-Specific Demethylase 1 Inhibitor: Summary and Perspective,” Journal of Medicinal Chemistry 63, no. 23 (2020): 14197–14215.

[282] M. M. Tayari, H. G. Dos Santos, and F. Beckedorff, “Co-targeting Menin and LSD1 Dismantles Oncogenic Programs and Restores Differentiation in MLL-rearranged AML,” BioRxiv (2025).

[283] A. Maiques-Diaz, G. J. Spencer, J. T. Lynch, et al., “Enhancer Activation by Pharmacologic Displacement of LSD1 from GFI1 Induces Differentiation in Acute Myeloid Leukemia,” Cell reports 22, no. 13 (2018): 3641–3659.

[284] Z. Feng, Y. Yao, C. Zhou, et al., “Pharmacological Inhibition of LSD1 for the Treatment of MLL-rearranged Leukemia,” Journal of hematology & oncology 9 (2016): 24.

[285] H. P. Mohammad, K. N. Smitheman, C. D. Kamat, et al., “A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC,” Cancer Cell 28, no. 1 (2015): 57–69.

[286] T. Maes, C. Mascaró, I. Tirapu, et al., “ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia,” Cancer Cell 2018; 33(3): 495–511.e12.

[287] T. Somervaille, O. Salamero, P. Montesinos, et al., “Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Ac Tivity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Ly Sine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results fro M a First-in-Human Phase 1 Study,” Blood 128, no. 22 (2016): 4060–4060.

[288] K. Sakamoto, T. Imamura, M. Yano, et al., “Sensitivity of MLL-rearranged AML Cells to all-trans Retinoic Acid Is Associated With the Level of H3K4me2 in the RARα Promoter Region,” Blood Cancer Journal 4, no. 4 (2014): e205.

[289] G. Deb, B. Wingelhofer, F. M. R. Amaral, et al., “Pre-clinical Activity of Combined LSD1 and mTORC1 Inhibition in MLL-translocated Acute Myeloid Leukaemia,” Leukemia 34, no. 5 (May 2020): 1266–1277.

[290] S. S. Dhar, C. Brown, A. Rizvi, et al., “Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS,” Cell reports 44, no. 5 (2025): 115619.

[291] F. Wang, D. Chen, P. Wu, et al., “Formaldehyde, Epigenetics, and Alzheimer's Disease,” Chemical Research in Toxicology 32, no. 5 (2019): 820–830.

[292] H. Yang, S. Maddipoti, A. Quesada, et al., “Analysis of Class I and II Histone Deacetylase Gene Expression in human Leukemia,” Leukemia & lymphoma 56, no. 12 (2015): 3426–3433.

[293] S. Ropero and M. Esteller, “The Role of Histone Deacetylases (HDACs) in human Cancer,” Molecular Oncology 1, no. 1 (2007): 19–25.

[294] C. A. Bradbury, F. L. Khanim, R. Hayden, et al., “Histone Deacetylases in Acute Myeloid Leukaemia Show a Distinctive Pattern of Expression That Changes Selectively in Response to Deacetylase Inhibitors,” Leukemia 19, no. 10 (2005): 1751–1759.

[295] P. Marks, R. A. Rifkind, V. M. Richon, et al., “Histone Deacetylases and Cancer: Causes and Therapies,” Nature Reviews Cancer 1, no. 3 (2001): 194–202.

[296] J. Chen, D. A. Santillan, M. Koonce, et al., “Loss of MLL PHD Finger 3 Is Necessary for MLL-ENL-induced Hematopoietic Stem Cell Immortalization,” Cancer Research 68, no. 15 (2008): 6199–6207.

[297] T. Verbeek, K. S. Vrenken, S. Arentsen-Peters, et al., “Selective Inhibition of HDAC Class IIA as Therapeutic Intervention for KMT2A-rearranged Acute Lymphoblastic Leukemia,” Communications Biology 7, no. 1 (2024): 1257.

[298] O. A. O'Connor, M. L. Heaney, L. Schwartz, et al., “Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies,” Journal of Clinical Oncology 24, no. 1 (2006): 166–173.

[299] A. C. West and R. W. Johnstone, “New and Emerging HDAC Inhibitors for Cancer Treatment,” Journal of Clinical Investigation 124, no. 1 (2014): 30–39.

[300] J. Yao, G. Li, Z. Cui, et al., “The Histone Deacetylase Inhibitor I1 Induces Differentiation of Acute Leukemia Cells with MLL Gene Rearrangements via Epigenetic Modification,” Frontiers in Pharmacology 13 (2022): 876076.

[301] P. Garrido Castro, E. H. J. van Roon, and S. S. Pinhanços, “The HDAC Inhibitor Panobinostat (LBH589) Exerts in Vivo Anti-leukaemic Activity Against MLL-rearranged Acute Lymphoblastic Leukaemia and Involves the RNF20/RNF40/WAC-H2B Ubiquitination Axis,” Leukemia 32, no. 2 (2018): 323–331.

[302] R. D. Morin, M. Mendez-Lago, A. J. Mungall, et al., “Frequent Mutation of Histone-modifying Genes in non-Hodgkin Lymphoma,” Nature 476, no. 7360 (2011): 298–303.

[303] L. Pasqualucci, D. Dominguez-Sola, A. Chiarenza, et al., “Inactivating Mutations of Acetyltransferase Genes in B-cell Lymphoma,” Nature 471, no. 7337 (2011): 189–195.

[304] J. Zhang, D. Dominguez-Sola, S. Hussein, et al., “Disruption of KMT2D Perturbs Germinal Center B Cell Development and Promotes Lymphomagenesis,” Nature Medicine 21, no. 10 (2015): 1190–1198.

[305] A. Ortega-Molina, I. W. Boss, A. Canela, et al., “The Histone Lysine Methyltransferase KMT2D Sustains a Gene Expression Program That Represses B Cell Lymphoma Development,” Nature Medicine 21, no. 10 (2015): 1199–1208.

[306] Y. Jiang, A. Ortega-Molina, H. Geng, et al., “CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas,” Cancer Discovery 7, no. 1 (2017): 38–53.

[307] C. L. Andersen, F. Asmar, T. Klausen, et al., “Somatic Mutations of the CREBBP and EP300 Genes Affect Response to Histone Deacetylase Inhibition in Malignant DLBCL Clones,” Leukemia Research Reports 2, no. 1 (2012): 1–3.

[308] M. Kalac, L. Scotto, E. Marchi, et al., “HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL,” Blood 118, no. 20 (2011): 5506–5516.

[309] E. Marchi, K. M. Zullo, J. E. Amengual, et al., “The Combination of Hypomethylating Agents and Histone Deacetylase Inhibitors Produce Marked Synergy in Preclinical Models of T-cell Lymphoma,” British Journal of Haematology 171, no. 2 (2015): 215–226.

[310] M. M. Ji, Y. H. Huang, J. Y. Huang, et al., “Histone Modifier Gene Mutations in Peripheral T-cell Lymphoma Not Otherwise Specified,” Haematologica 103, no. 4 (2018): 679–687.

[311] L. Jiang, Z. H. Gu, Z. X. Yan, et al., “Exome Sequencing Identifies Somatic Mutations of DDX3X in Natural Killer/T-cell Lymphoma,” Nature Genetics 47, no. 9 (2015): 1061–1066.

[312] A. R. Chakraborty, R. W. Robey, V. L. Luchenko, et al., “MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: Rationale to combine romidepsin with an MEK inhibitor,” Blood 121, no. 20 (2013): 4115–4125.

[313] C. L. Jones, C. M. Gearheart, S. Fosmire, et al., “MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia,” Blood 126, no. 19 (2015): 2202–2212.

[314] X. Yang and R. Huang, “Menin Inhibitors in KMT2A-rearranged Leukemia: Mechanistic Insights, Clinical Trial Progress, and Potential of Combination Therapies,” Leukemia Research 157 (2025): 107924.

[315] S. A. Dali, A. F. Al-Mashdali, A. Kalfah, et al., “Menin Inhibitors in KMT2A-rearranged and NPM1-mutated Acute Leukemia: A Scoping Review of Safety and Efficacy,” Critical Reviews in Oncology/Hematology 213 (2025): 104783.

[316] A. K. N. Chan and C. W. Chen, “Rewiring the Epigenetic Networks in MLL-Rearranged Leukemias: Epigenetic Dysregulation and Pharmacological Interventions,” Frontiers in Cell and Developmental Biology 7 (2019): 81.

[317] S. Cantilena, M. AlAmeri, and N. Che, “ynergistic Strategies for KMT2A-Rearranged Leukemias: Beyond Menin Inhibitor,” S 16, no. 23 (2024): 4017.

[318] D. J. Stumpel, P. Schneider, E. H. van Roon, et al., “Absence of Global Hypomethylation in Promoter Hypermethylated Mixed Lineage Leukaemia-rearranged Infant Acute Lymphoblastic Leukaemia,” European Journal of Cancer 49, no. 1 (2013): 175–184.

[319] D. J. Stumpel, P. Schneider, E. H. van Roon, et al., “Specific promoter methylation identifies different subgroups of MLL-rearranged infant acute lymphoblastic leukemia, influences clinical outcome, and provides therapeutic options,” Blood 114, no. 27 (2009): 5490–5498.

[320] C. Roolf, A. Richter, C. Konkolefski, et al., “Decitabine Demonstrates Antileukemic Activity in B Cell Precursor Acute Lymphoblastic Leukemia With MLL Rearrangements,” Journal of hematology & oncology 11, no. 1 (2018): 62.

[321] M. Kerstjens, E. M. Driessen, M. Willekes, et al., “MEK Inhibition Is a Promising Therapeutic Strategy for MLL-rearranged Infant Acute Lymphoblastic Leukemia Patients Carrying RAS Mutations,” Oncotarget 8, no. 9 (2017): 14835–14846.

[322] M. Kerstjens, S. S. Pinhancos, P. G. Castro, et al., “Trametinib Inhibits RAS-mutant MLL-rearranged Acute Lymphoblastic Leukemia at Specific Niche Sites and Reduces ERK Phosphorylation in Vivo,” Haematologica 103, no. 4 (2018): e147–e150.

[323] J. Ye, J. Zha, Y. Shi, et al., “Co-inhibition of HDAC and MLL-menin Interaction Targets MLL-rearranged Acute Myeloid Leukemia Cells via Disruption of DNA Damage Checkpoint and DNA Repair,” Clin Epigenetics 11, no. 1 (2019): 137.

[324] J. L. Kamens, S. Nance, C. Koss, et al., “Proteasome Inhibition Targets the KMT2A Transcriptional Complex in Acute Lymphoblastic Leukemia,” Nature Communications 14, no. 1 (2023): 809.

[325] G. C. Issa, B. Cuglievan, C. D. DiNardo, et al., “Early Results of the Phase I/II Study Investigating the All-Oral Combi Nation of the Menin Inhibitor Revumenib (SNDX-5613) With Decitabine/Ce Dazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE),” Blood 142, no. Supplement 1 (2023): 58.

[326] V. Ceolin, S. Ishimaru, S. E. Karol, et al., “The PedAL/EuPAL Project: A Global Initiative to Address the Unmet Medical Needs of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia,” Cancers (Basel) 16, no. 1 (2023): 78.

[327] J. Heward, L. Konali, and A. D'Avola, “KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas,” Blood 138, no. 5 (2021): 370–381.

[328] H. Kantarjian, F. Ravandi, and S. O'Brien, “Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia,” Blood 116, no. 22 (2010): 4422–4429.

[329] H. F. Fernandez, Z. Sun, X. Yao, et al., “Anthracycline Dose Intensification in Acute Myeloid Leukemia,” New England Journal of Medicine 361, no. 13 (2009): 1249–1259.

[330] F. Ravandi, A. K. Burnett, E. D. Agura, et al., “Progress in the treatment of acute myeloid leukemia,” Cancer 110, no. 9 (2007): 1900–1910.

[331] Z. Y. An and X. H. Zhang, “Menin inhibitors for acute myeloid leukemia: Latest updates from the 2023 ASH Annual Meeting,” Journal of hematology & oncology 17, no. 1 (2024): 52.

[332] W. C. Fiskus, C. P. Mill, C. Birdwell, et al., “Abstract 4028: Menin Inhibitor-based Combinations to Improve Efficacy and Overcome Resistance in AML,” Cancer Research 82, no. 12_Supplement (2022): 4028–4028.

[333] A. M. Zeidan, E. S. Wang, G. C. Issa, et al., “Ziftomenib Combined With Intensive Induction (7+3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia: Interim Phase 1a Results From KOMET-007,” Blood 144, no. Supplement 1 (2024): 214–214.

[334] K. Oncology and K. Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress. June 12–15, 2025, Milan, Italy.

[335] A. M. Zeidan, E. Wang, A. Fathi, et al., “AML-732: Ziftomenib Combined with Intensive Induction Chemotherapy (7+ 3) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results from KOMET-007,” Clinical Lymphoma Myeloma and Leukemia 2025; 25: S452–S453.

[336] J. Kale, E. J. Osterlund, and D. W. Andrews, “BCL-2 family Proteins: Changing Partners in the Dance towards Death,” Cell Death and Differentiation 25, no. 1 (2018): 65–80.

[337] G. F. Perini, G. N. Ribeiro, and J. V. Pinto Neto, “BCL-2 as Therapeutic Target for Hematological Malignancies,” Journal of Hematology & Oncology 11, no. 1 (2018): 65.

[338] M. Konopleva, D. A. Pollyea, J. Potluri, et al., “Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia,” Cancer Discovery 6, no. 10 (2016): 1106–1117.

[339] R. Pan, L. J. Hogdal, J. M. Benito, et al., “Selective BCL-2 Inhibition by ABT-199 Causes on-target Cell Death in Acute Myeloid Leukemia,” Cancer Discovery 4, no. 3 (2014): 362–375.

[340] C. D. DiNardo, K. W. Pratz, A. Letai, et al., “Safety and Preliminary Efficacy of Venetoclax With Decitabine or Azacitidine in Elderly Patients With Previously Untreated Acute Myeloid Leukaemia: A Non-randomised, Open-label, Phase 1b Study,” The Lancet Oncology 19, no. 2 (2018): 216–228.

[341] A. H. Wei, S. A. Strickland, and J. Z. Hou, “Venetoclax Combined with Low-Dose Cytarabine for Previously Untreated Patients with Acute Myeloid Leukemia: Results from a Phase Ib/II Study,” Journal of Clinical Oncology 37, no. 15 (2019): 1277–1284.

[342] B. Z. Carter, W. Tao, P. Y. Mak, et al., “Menin Inhibition Decreases Bcl-2 and Synergizes With Venetoclax in NPM 1/FLT3-mutated AML,” Blood 138, no. 17 (2021): 1637–1641.

[343] Q. Ling, Y. Zhou, Y. Qian, et al., “Repressing HIF-1α-induced HDAC9 Contributes to the Synergistic Effect of Venetoclax and MENIN Inhibitor in KMT2Ar AML,” Biomarker Research 11, no. 1 (2023): 105.

[344] M. Fleischmann, J. Bechwar, D. Voigtländer, et al., “Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation,” Cancers (Basel) 16, no. 7 (2024): 1311.

[345] X. Zhou, L. Zhang, S. Aryal, et al., “Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia,” Blood 144, no. 19 (2024): 2018–2032.

[346] X. Zhou, L. Zhang, S. Aryal, et al., “Decoding the Epigenetic Drivers of Menin-MLL Inhibitor Resistance in K MT2A-Rearranged Acute Myeloid Leukemia,” Blood 142, no. Supplement 1 (2023): 587–587.

[347] F. El Chaer, M. Keng, and K. K. Ballen, “MLL-Rearranged Acute Lymphoblastic Leukemia,” Curr Hematol Malig Rep 15, no. 2 (2020): 83–89.

[348] M. M. Dzama, M. Steiner, J. Rausch, et al., “Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition,” Blood 136, no. 21 (2020): 2442–2456.

[349] K. V. G. Nadiminti, K. D. Sahasrabudhe, and H. Liu, “Menin Inhibitors for the Treatment of Acute Myeloid Leukemia: Challenges and Opportunities Ahead,” Journal of hematology & oncology 17, no. 1 (2024): 113.

[350] H. Zhang, Y. Pang, L. Yi, et al., “Epigenetic Regulators Combined With Tumour Immunotherapy: Current Status and Perspectives,” Clin Epigenetics 17, no. 1 (2025): 51.

[351] S. P. Kubli, T. Berger, D. V. Araujo, et al., “Beyond Immune Checkpoint Blockade: Emerging Immunological Strategies,” Nature Reviews Drug Discovery 20, no. 12 (2021): 899–919.

[352] X. He and C. Xu, “Immune Checkpoint Signaling and Cancer Immunotherapy,” Cell Research 30, no. 8 (2020): 660–669.

[353] W. Cao, Y. Xie, L. Cai, et al., “Pan‑cancer analysis on the role of KMT2C expression in tumor progression and immunotherapy,” Oncology letters 28, no. 3 (2024): 444.

[354] R. Zhang, H. X. Wu, M. Xu, et al., “KMT2A/C Mutations Function as a Potential Predictive Biomarker for Immunotherapy in Solid Tumors,” Biomarker Research 8, no. 1 (2020): 71.

[355] Y. Shi, Y. Lei, L. Liu, et al., “Integration of Comprehensive Genomic Profiling, Tumor Mutational Burden, and PD-L1 Expression to Identify Novel Biomarkers of Immunotherapy in Non-small Cell Lung Cancer,” Cancer Medicine 10, no. 7 (2021): 2216–2231.

[356] R. Liu, Y. Niu, C. Liu, et al., “Association of KMT2C/D Loss-of-function Variants With Response to Immune Checkpoint Blockades in Colorectal Cancer,” Cancer Science 114, no. 4 (2023): 1229–1239.

[357] A. B. Leahy, K. J. Devine, Y. Li, et al., “Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapy,” Blood 139, no. 14 (2022): 2173–2185.

[358] J. G. Rossi, A. R. Bernasconi, C. N. Alonso, et al., “Lineage Switch in Childhood Acute Leukemia: An Unusual Event With Poor Outcome,” American Journal of Hematology 87, no. 9 (2012): 890–897.

[359] M. J. Oberley, P. S. Gaynon, D. Bhojwani, et al., “Myeloid lineage switch following chimeric antigen receptor T-cell therapy in a patient with TCF3-ZNF384 fusion-positive B-lymphoblastic leukemia,” Pediatric Blood & Cancer 65, no. 9 (2018): e27265.

[360] G. Mo, H. W. Wang, A. C. Talleur, et al., “Diagnostic Approach to the Evaluation of Myeloid Malignancies Following CAR T-cell Therapy in B-cell Acute Lymphoblastic Leukemia,” Journal for ImmunoTherapy of Cancer 8, no. 2 (2020): e001563.

[361] R. Gardner, D. Wu, S. Cherian, et al., “Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy,” Blood 127, no. 20 (2016): 2406–2410.

[362] M. A. Nix, K. Mandal, H. Geng, et al., “Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CAR-T Cells in KMT2A/MLL1-Rearranged B-ALL,” Cancer Discovery 11, no. 8 (2021): 2032–2049.

[363] L. M. Niswander, Z. T. Graff, C. D. Chien, et al., “Potent Preclinical Activity of FLT3-directed Chimeric Antigen Receptor T-cell Immunotherapy Against FLT3- mutant Acute Myeloid Leukemia and KMT2A-rearranged Acute Lymphoblastic Leukemia,” Haematologica 108, no. 2 (2023): 457–471.

[364] M. Suematsu, S. Yagyu, H. Yoshida, et al., “Targeting FLT3-specific Chimeric Antigen Receptor T Cells for Acute Lymphoblastic Leukemia With KMT2A Rearrangement,” Cancer Immunology, Immunotherapy 72, no. 4 (2023): 957–968.

[365] H. Ren, N. Elliott, B. Lye, et al., “Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia,” Blood 147, no. 2 (J2026): 180–196.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.